As of November 6, 2026, Theravance Biopharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 23, 2026 (Form 8-K, June 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Theravance Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Theravance Biopharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-23. Every row below is cited to the filing it comes from, and this page adds each new change as Theravance Biopharma, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-03-03 (layoff filings and notices).
Also on the record for Theravance Biopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 25, 2026 | Stake report, Schedule 13D/A, by Weiss Asset Management LP | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Madison Avenue International LP | 17.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Newtyn Management, LLC | 6.7% of the class | 5%+ stakes | Source |
| March 25, 2026 | Stake report, Schedule 13D/A, by Weiss Asset Management LP | 14.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Newtyn Management, LLC | 8.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Theravance Biopharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Theravance Biopharma, Inc. and the records around it.
Theravance Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Mar 2026
Companies that share a holder
- Weiss Asset Management LP also filed stake reports on 9 other companies: RE/MAX Holdings, Inc. (Aug 2026), Canaan Inc. (Aug 2026), APARTMENT INVESTMENT & MANAGEMENT CO (May 2026)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- Newtyn Management, LLC also filed stake reports on 13 other companies: Par Technology Corporation (Aug 2026), QuidelOrtho Corporation (Aug 2026), ZOOZ Strategy Ltd. (Aug 2026)
Watch Theravance Biopharma, Inc.
Get an email when Theravance Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Theravance Biopharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Theravance Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Theravance Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-23 | Reported | not named in the filing | 8-K, 2026-06-23 |
New leaders reset buying decisions — get the Full Report on Theravance Biopharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Theravance Biopharma, Inc., with the record behind each one.
Find candidates like senior executive at Theravance Biopharma, Inc.Every change, in the filing's words
Reported
(b) and (e) On June 19, 2026, Theravance Biopharma Ireland Limited, a subsidiary of the Registrant Theravance Biopharma, Inc. (together, the "Company"), entered into a compromise agreement (the "Compromise Agreement") with ine Miller, the Company's Senior Vice President, Development and Head of Ireland Office, pursuant to which Dr. Miller's employment with the Company will terminate (the "Termination") on November 15, 2026 (the "Termination Date") in connection with the restructuring announced by the Company in March 2026 (the "Restructuring").
- The Compromise Agreement provided for compensation and other terms consistent with the Employment Agreement entered into between Dr. Miller and the Company on February 10, 2020, as amended on February 8, 2026.
- In connection with the Termination, the Company also entered into a pension side letter (the "Side Letter") with Dr. Miller, pursuant to which the Company will make a special contribution for the benefit of Dr. Miller in the amount of $250,000 within 30 days of the Termination Date.
- On June 19, 2026, Dr. Miller received a grant of 18,750 restricted share units.
- The grant was made in connection with Dr. Miller's continued service to the Company through the Termination Date.
- The foregoing descriptions of the Compromise Agreement and Side Letter do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, copies of which the Company intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2026.
Tools for this story
Each opens in a new tab, filled in for Theravance Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.